Alexander Philipovskiy

Prof. Dr. Alexander Philipovskiy

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2020 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
APAlexander Philipovskiy
Alexander Philipovskiy
ACAleli Campbell
Aleli Campbell
RHRosalinda Heydarian
Rosalinda Heydarian
BCBrenda Castillo
Brenda Castillo
ADAlok K. Dwivedi
Alok K. Dwivedi
ZNZeina Nahleh
Zeina Nahleh
Aim: The purpose of this study was to determine the level of adherence to adjuvant aromatase inhibitor (AI) therapy and factors associated with non-adherence among Hispanic/Latino women with hormonal receptor-positive breast cancer (BC) treated at an academic center at the American–Mexican border city of El Paso, TX. Patients and Methods: Institutional Review Board approval was obtained in this cross-sectional study using the validated Morisky Medication Adherence Scale to assess patient adherence to AI therapy. Patients diagnosed with stage I-III hormonal receptor-positive, human epidermal growth factor receptor 2-negative BC who were on adjuvant AIs therapy were recruited from the Texas Tech University Health Sciences Center El Paso breast clinic. Results: Between September 2017 and August 2018, 122 consecutive patients were enrolled; 119 were analyzed, three were lost to follow up. The mean age was 61.6±9.4 years, and 109 (91.6%) self-identified as Hispanic/Latino. A total of 58% reported an annual income of $15,000 or less. Overall, 40.3% had completed eighth grade or less education, 31.9% high school, and 12% had obtained a technical degree. The majority of patients (56%) had either a medium (45%) or a low level of adherence (11%). High adherence was noted in 44% of participants. Seven (5.6%) patients scored 2 or below on a 4–point scale for intentional adherence, and 18 (13.5%) scored 2 or below on a 4-point scale for unintentional adherence. Conclusion: These data suggest that the majority of Hispanic/Latino women with breast cancer have medium or low levels of adherence to therapy with AIs. Factors associated with medium and low adherence were unintentional (forgetfulness), but also included intentional factors, such as avoidance of adverse effects and delays with obtaining refills (cost-related nonadherence).

4 April 2022 in HPB
Verified
Journal Article
Closed access
FMFelipe B. Maegawa
Felipe B. Maegawa
MAMaria Ahmad
Maria Ahmad
KAKatherine Aguirre
Katherine Aguirre
SESherif Elhanafi
Sherif Elhanafi
SCShintaro Chiba
Shintaro Chiba
Ioannis KonstantinidisIoannis Konstantinidis
Ioannis Konstantinidis

18 December 2017 in American Journal of Case Reports
Verified
Journal Article
Open access
PDF file
YFYvette Farran
Yvette Farran
OPOsvaldo Padilla
Osvaldo Padilla
KCKarinn Chambers
Karinn Chambers
APAlexander Philipovskiy
Alexander Philipovskiy
ZNZeina Nahleh
Zeina Nahleh
BACKGROUND:Radiation-associated breast angiosarcoma is a rare clinical entity that is thought to be increasing in incidence. CASE REPORT:Here we present the case of a 67-year-old female with a history of left breast invasive ductal carcinoma who rece...

4 September 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
APAlexander Philipovskiy
Alexander Philipovskiy
ADAlok K. Dwivedi
Alok K. Dwivedi
RGRoberto Gamez
Roberto Gamez
RMRichard McCallum
Richard McCallum
DMDebabrata Mukherjee
Debabrata Mukherjee
SGSumit Gaur
Sumit Gaur
Triple-negative breast cancer (TNBC) represents 15%–20% of all breast cancer types. It is more common among African American (AA) and Hispanic-Latina (HL) women. The biology of TNBC in HL women has been poorly characterized, but some data suggest that the molecular drivers of breast cancer might differ. There are no clinical tools to aid medical oncologists with decisions regarding appropriate individualized therapy, and no way to predict long-term outcomes. The aim of this study was to characterize individual patient gene mutation profiles and to identify the relationship with clinical outcomes. We collected formalin-fixed paraffin-embedded tumors (FFPE) from women with TNBC. We analyzed the gene mutation profiles of the collected tumors and compared the results with individual patient’s clinical histories and outcomes. Of 25 patients with TNBC, 24 (96%) identified as HL. Twenty-one (84%) had stage III–IV disease. The most commonly mutated genes were TP53, NOTCH1, NOTCH2, NOTCH3, AKT, MEP3K, PIK3CA, and EGFR. Compared with other international cancer databases, our study demonstrated statistically significant higher frequencies of these genes among HL women. Additionally, a worse clinical course was observed among patients whose tumors had mutations in NOTCH genes and PIK3CA. This study is the first to identify the most common genetic alterations among HL women with TNBC. Our data strongly support the notion that molecular drivers of breast cancer could differ in HL women compared with other ethnic backgrounds. Therefore, a deeper understanding of the biological mechanisms behind NOTCH gene and PIK3CA mutations may lead to a new treatment approach.

19 December 2021 in Materials
Verified
Journal Article
Open access
PDF file
ACAleli Campbell
Aleli Campbell
DGDenisse A Gutierrez
Denisse A Gutierrez
CKColin D Knight
Colin D Knight
CVCharlotte M. Vines
Charlotte M. Vines
RHRosalinda Heydarian
Rosalinda Heydarian
Thomas BolandThomas Boland
Thomas Boland
Background: Breast cancer (BC) continues to have the second highest mortality amongst women in the United States after lung cancer. For 2021, the American Cancer Association predicted 281,550 new invasive breast cancer cases besides 49,290 new cases of non-invasive breast cancer and 43,600 deaths from the metastatic disease. A treatment modality is radiation therapy, which is given for local control as well as palliation of patient symptoms. The initial step of new drug development is in-vitro cell studies, which help describe new drug properties and toxicities. However, these models are not optimal, and better ones have yet to be determined. This study uses bioprinting technology to elucidate the sensitivity of tumor cells to the combination of palbociclib (PD) and letrozole (Let) treatment. We hypothesize that this technology could serve as a model to predict treatment outcomes more efficiently. Methods: The breast cancer cell lines MCF7 and MDA-MB-231 as well as the normal breast epithelial cell line, MCF-10A, were treated with PD-Let with and without radiotherapy (RT), and cell viability was compared in pairwise fashion for thermally inkjet bioprinted (TIB) and manually seeded (MS) cells. Results: In absence of radiation, the TIB MCF7 cells have 2.5 times higher viability than manually seeded (MS) cells when treated with 100 µM palbociclib and 10 µM letrozole, a 36% higher viability when treated with 50 µM palbociclib and 10 µM letrozole, and an 8% higher viability when treated with 10 µM palbociclib and 10 µM letrozole. With 10 Gy of radiation, TIB cells had a 45% higher survival rate than MS cells at the lowest palbociclib concentration and a 29% higher survival rate at the intermediate palbociclib concentration. Without radiation treatment, at a concentration of 10 μM PD-Let, TIB MDA-MB-231 cells show a 8% higher viability than MS cells when treated with 10 µM PD and 10 µM Let; at higher drug concentrations, the differences disappeared, but some 1.7% of the TIB MDA-MB-231 cells survived exposure to 150 μM of PD + 10 μM letrozole vs. none of the MS cells. These cells are more radiation sensitive than the other cell lines tested and less sensitive to the combo drug treatments. We observed an 18% higher survival of TIB MCF-10A cells without radiation treatment when exposed to 10 μM PD + 10 μM Let but no difference in cell survival between the two groups when radiation was applied. Independent of growth conditions, TIB cells did not show more resistance to radiation treatment than MS cells, but a higher resistance to the combo treatment was observed, which was most pronounced in the MCF-7 cell line. Conclusion: Based on these results, we suggest that TIB used in in-vitro models could be a feasible strategy to develop and/or test new anticancer drugs.

6 July 2019 in In Vivo
Verified
Journal Article
Open access
PDF file
APAlexander Philipovskiy
Alexander Philipovskiy
JCJavier Corral
Javier Corral
KDKumar Alok Dwivedi
Kumar Alok Dwivedi
RHRosalinda Heydarian
Rosalinda Heydarian
SGSumit Gaur
Sumit Gaur
Background/Aim: The aim of the study was to investigate the efficacy of neoadjuvant and chemotherapy (NACT) and adjuvant chemotherapy (ACT) in Hispanic/Latino (H/L) women with TNBC. Patients and Methods: We reviewed the charts of patients with TNBC, stages I–III, treated at TTUHSC from 2006 to 2016. Overall survival (OS) and recurrence-free survival (RFS) were estimated and compared between the treatment groups. Kaplan–Meier curve and Cox proportional hazards regression analyses were conducted to estimate unadjusted and adjusted effects of NACT compared to ACT. Results: A total of 104 patients with TNBC, 30 (29%) received NACT and 74 (71%) ACT. Women undergoing NACT were younger, with a mean age of 50.8 years. Of the 30 patients who received NACT, 12 (40%) had pathologically complete response (pCR). Women who achieved pCR had an excellent RFS (HR=0.5, p=0.001). Women with residual cancer after NACT had worse outcome compared to patients who received ACT (HR=1.7, p=0.005). Conclusion: pCR to NACT is a powerful surrogate for OS in H/L women with TNBC.